Pectin

Summary

Pectin (CHEMBL2108751) is a phase-3 clinical-stage unknown (ATC A07BC01); indicated across 7 conditions including irritable bowel syndrome and constipation disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: A07BC01
• Indications: 7 conditions
• Clinical trials: 23

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108751
Name	Pectin
Type	Unknown
Max phase	3
ATC	A07BC01

Also known as: Apple pectin, Citrus pectin, E-440, INS NO.440, INS-440, Pectin, apple, citrus, Pectins, PECTIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
irritable bowel syndrome	3	MONDO:0005052	EFO:0000555
constipation disorder	3	MONDO:0002203	HP:0002019
Crohn disease	2	MONDO:0005011	EFO:0000384
sickle cell disease	2	MONDO:0011382	MONDO:0011382
neoplasm	2	MONDO:0005070	MONDO:0004992
nutritional disorder	1	MONDO:0005137	EFO:0001069

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 23.

Phase distribution

Phase	Trials
Not specified	11
PHASE2	4
PHASE3	2
PHASE2/PHASE3	2
PHASE4	1
PHASE1/PHASE2	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02376270	PHASE4	COMPLETED	Pectin, Aging and Intestinal Barrier Function
NCT02194972	PHASE3	COMPLETED	Clinical Effects of Soluble Dietary Fiber Supplementation
NCT02270268	PHASE3	COMPLETED	Effects of Pectin Supplementation in Diarrhea-predominant Irritable Bowel Syndrome
NCT04191213	PHASE2/PHASE3	UNKNOWN	Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients
NCT04381871	PHASE2/PHASE3	UNKNOWN	Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients
NCT06531993	PHASE2	NOT_YET_RECRUITING	Effect of Pectin in Chronic Kidney Disease Patients ( Stage 3 and 4 )
NCT02164877	PHASE2	TERMINATED	Effect of Soluble Dietary Fiber on Bacterial Translocation in Crohn’s Disease
NCT02291354	PHASE2	UNKNOWN	Evaluating the Synergism of Soluble Dietary Fiber With Fecal Microbiota Transplantation in Slow Transit Constipation
NCT02379624	PHASE1/PHASE2	COMPLETED	Pectin Start Early Enteral Nutritional Support in Critically Ill Patients
NCT02844426	PHASE2	COMPLETED	Effect of a Synbiotic on Symptoms of Patients With STC
NCT01756651	PHASE1	COMPLETED	Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures
NCT07423663	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Antimicrobial Effect of Calcium Silicate and Pectin as Intracanal Medications in Necrotic Teeth With Periapical Lesions
NCT06955975	Not specified	RECRUITING	The Effect of Pectin Supplementation on Geriatric With Frailty: A Randomised Placebo-Controlled Dietary Intervention Study
NCT07093346	Not specified	RECRUITING	The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT00895193	Not specified	COMPLETED	Alternative Options to Minimize Niacin-Induced Flushing
NCT01257295	Not specified	COMPLETED	Properties of Dietary Fibre and Energy Intake
NCT02016469	Not specified	UNKNOWN	Effects of Pectin on Flora Intestinal Colonization and Maintenance After Fecal Transplantation
NCT04114513	Not specified	WITHDRAWN	Dietary Fibers Effect on the Gut Microbiota Composition
NCT04215380	Not specified	UNKNOWN	Effects of Gum Arabic Ingestion on Hormonal and Metabolic Changes in Patients With Polycystic Ovary Syndrome
NCT04224168	Not specified	UNKNOWN	Pectin Use in Pediatric Intestinal Rehabilitation
NCT06426134	Not specified	COMPLETED	Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS
NCT06580132	Not specified	COMPLETED	The Effects of Dietary Fibres on Metabolic Health and the Gut Microbiome
NCT06758570	Not specified	COMPLETED	Effect Dietary Fibre Supplementation on Gut Microbiota Composition

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).